Jennifer Lauchle

1.3k total citations
23 papers, 833 citations indexed

About

Jennifer Lauchle is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Jennifer Lauchle has authored 23 papers receiving a total of 833 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 8 papers in Hematology and 7 papers in Oncology. Recurrent topics in Jennifer Lauchle's work include Acute Myeloid Leukemia Research (6 papers), Advanced Breast Cancer Therapies (5 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Jennifer Lauchle is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Advanced Breast Cancer Therapies (5 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Jennifer Lauchle collaborates with scholars based in United States, France and United Kingdom. Jennifer Lauchle's co-authors include Kevin Shannon, Benjamin S. Braun, Scott C. Kogan, Jon Akutagawa, Michelle M. Le Beau, Mignon L. Loh, Doan Le, Luis F. Parada, Jill Fredrickson and Saoirse Dolly and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Jennifer Lauchle

23 papers receiving 821 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer Lauchle United States 13 512 243 203 181 153 23 833
Rosalind H. Gunby Italy 13 316 0.6× 267 1.1× 180 0.9× 222 1.2× 90 0.6× 17 683
Elena Tirrò Italy 19 423 0.8× 265 1.1× 261 1.3× 303 1.7× 123 0.8× 48 1.0k
J Lyons Germany 8 256 0.5× 424 1.7× 123 0.6× 201 1.1× 81 0.5× 11 775
Alicja Gruszka Italy 20 395 0.8× 274 1.1× 259 1.3× 378 2.1× 60 0.4× 36 945
Leila R. Martins Portugal 14 652 1.3× 256 1.1× 312 1.5× 193 1.1× 93 0.6× 21 1.1k
Artur Gontarewicz Germany 14 290 0.6× 187 0.8× 311 1.5× 140 0.8× 39 0.3× 26 727
Tony DeBlasio United States 11 575 1.1× 267 1.1× 421 2.1× 77 0.4× 184 1.2× 15 1.0k
Nadia Coltella Italy 16 387 0.8× 108 0.4× 194 1.0× 68 0.4× 114 0.7× 24 709
V. Sandor United States 8 393 0.8× 158 0.7× 183 0.9× 310 1.7× 58 0.4× 14 736
Thomas Strömberg Sweden 12 503 1.0× 206 0.8× 214 1.1× 59 0.3× 34 0.2× 15 744

Countries citing papers authored by Jennifer Lauchle

Since Specialization
Citations

This map shows the geographic impact of Jennifer Lauchle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Lauchle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Lauchle more than expected).

Fields of papers citing papers by Jennifer Lauchle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Lauchle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Lauchle. The network helps show where Jennifer Lauchle may publish in the future.

Co-authorship network of co-authors of Jennifer Lauchle

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Lauchle. A scholar is included among the top collaborators of Jennifer Lauchle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Lauchle. Jennifer Lauchle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chandarlapaty, Sarat, Maura N. Dickler, José Alejandro Pérez Fidalgo, et al.. (2023). An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research. 29(15). 2781–2790. 7 indexed citations
2.
Metcalfe, Ciara & Jennifer Lauchle. (2022). Clinical Translation: Targeting the Estrogen Receptor. Advances in experimental medicine and biology. 1390. 297–309. 3 indexed citations
3.
4.
Daemen, Anneleen, Jill M. Spoerke, Wei Zhou, et al.. (2020). Abstract P2-11-05: ER pathway activity signature as a biomarker for endocrine agent GDC-9545. Cancer Research. 80(4_Supplement). P2–11. 1 indexed citations
5.
Infante, Jeffrey R., Antoine Hollebecque, Sophie Postel‐Vinay, et al.. (2016). Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors. Clinical Cancer Research. 23(10). 2423–2432. 59 indexed citations
6.
Dolly, Saoirse, Andrew J. Wagner, Johanna C. Bendell, et al.. (2016). Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(12). 2874–2884. 105 indexed citations
7.
Makker, Vicky, Fernando O. Recio, Ling Ma, et al.. (2016). A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer. 122(22). 3519–3528. 64 indexed citations
8.
Infante, Jeffrey R., Antoine Hollebecque, Sophie Postel‐Vinay, et al.. (2015). Abstract CT139: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors. Cancer Research. 75(15_Supplement). CT139–CT139. 5 indexed citations
9.
Makker, Vicky, Fernando O. Recio, Ling Ma, et al.. (2014). Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.. Journal of Clinical Oncology. 32(15_suppl). 5513–5513. 12 indexed citations
10.
Chang, Tiffany, Jin Xu, Jon Akutagawa, et al.. (2012). Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. Journal of Clinical Investigation. 123(1). 335–339. 101 indexed citations
11.
Lyubynska, Natalya, Matthew F. Gorman, Jennifer Lauchle, et al.. (2011). A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice. Science Translational Medicine. 3(76). 76ra27–76ra27. 71 indexed citations
12.
Rauen, Katherine A., Anuradha Banerjee, W. Robert Bishop, et al.. (2011). Costello and cardio‐facio‐cutaneous syndromes: Moving toward clinical trials in RASopathies. American Journal of Medical Genetics Part C Seminars in Medical Genetics. 157(2). 136–146. 41 indexed citations
13.
Hollebecque, Antoine, Andrew R. Clamp, Laura Horsley, et al.. (2011). Abstract B153: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered once weekly (QW).. Molecular Cancer Therapeutics. 10(11_Supplement). B153–B153. 6 indexed citations
14.
Wagner, Amy J., Johanna C. Bendell, Saoirse Dolly, et al.. (2011). A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3020–3020. 60 indexed citations
15.
Lyubynska, Natalya, Jennifer Lauchle, Kevin Shannon, & Benjamin S. Braun. (2009). Treatment with a MEK Inhibitor Improves Myeloproliferation, Anemia and Survival in a Mouse Model of CMML and JMML.. Blood. 114(22). 966–966. 1 indexed citations
16.
Lauchle, Jennifer, Doan Le, Doris Kim, et al.. (2007). Mutations That Cooperate with Nf1 Inactivation in Leukemogenesis Influence Therapeutic Response to MEK Inhibition.. Blood. 110(11). 594–594. 2 indexed citations
17.
Kim, Andrew, Kelly Morgan, Diane E. Hasz, et al.. (2006). β common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice. Blood. 109(4). 1687–1691. 21 indexed citations
18.
Lauchle, Jennifer, Benjamin S. Braun, Mignon L. Loh, & Kevin Shannon. (2005). Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatric Blood & Cancer. 46(5). 579–585. 63 indexed citations
19.
Bonifas, Jeannette M., Jennifer Lauchle, Christian P. Kratz, et al.. (2005). Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. Genomics. 85(5). 600–607. 37 indexed citations
20.
Le, Doan, Yuan Zhu, Jennifer Lauchle, et al.. (2004). Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 103(11). 4243–4250. 137 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rosalind H. Gunby Breakdown of academic impact, for papers by Elena Tirrò Breakdown of academic impact, for papers by J Lyons Breakdown of academic impact, for papers by Alicja Gruszka Breakdown of academic impact, for papers by Leila R. Martins Breakdown of academic impact, for papers by Artur Gontarewicz Breakdown of academic impact, for papers by Tony DeBlasio Breakdown of academic impact, for papers by Nadia Coltella Breakdown of academic impact, for papers by V. Sandor Breakdown of academic impact, for papers by Thomas Strömberg
Rankless by CCL
2026